CMPS

COMPASS Pathways plc [CMPS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CMPS Stock Summary

Top CMPS Correlated Resources

CMPS

Top 10 Correlated ETFs

CMPS

Top 10 Correlated Stocks

CMPS

In the News

02:46 22 Mar 2023 CMPS

COMPASS Pathways earns repeat ‘Buy' rating and US$60 price target on adjusted trial design for COMP360

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy' rating and US$60 price target for COMPASS Pathways after the mental health care company adjusted the trial design for its COMP360 phase 3 program investigating psilocybin for treatment-resistant depression (TRD). “We are not making any major changes to our model post-4Q22 results,” the analysts wrote in a note to clients.

08:30 22 Mar 2023 CMPS

2 Growth Stocks With Incredible Potential in the Next 5 Years

Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.

10:23 22 Mar 2023 CMPS

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows:

12:01 22 Mar 2023 CMPS

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

Conference call to be held at 8:00am ET (1:00pm UK) Conference call to be held at 8:00am ET (1:00pm UK)

05:52 22 Mar 2023 CMPS

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

These stocks are risky. But they just might deliver huge gains if analysts are right.

08:28 22 Mar 2023 CMPS

7 Tempting Sin Stocks to Buy for Promising Profits

Following a rough year, investors seeking positive returns might want to consider going a bit controversial with sin stocks. Understandably, with the political winds turning progressive, people nowadays turn a stink eye toward cynicism.

02:30 22 Mar 2023 CMPS

The 7 Most Promising Psychedelic Stocks to Buy in February

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

11:45 22 Mar 2023 CMPS

Psychedelic Sunday: Competitive Strategies

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

01:33 22 Mar 2023 CMPS

All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy

COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11:17 22 Mar 2023 CMPS

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

CMPS Financial details

Company Rating

Neutral

Market Cap

356.22M

Income

-91.51M

Revenue

Book val./share

4.27

Cash/share

3.37

Dividend

Dividend %

Employees

116

Optionable

Shortable

Yes

Earnings

28 Feb 2023

P/E

-4.33

Forward P/E

PEG

-2.09

P/S

P/B

2.18

P/C

2.77

P/FCF

-3.76

Quick Ratio

10.18

Current Ratio

12.29

Debt / Equity

0.09

LT Debt / Equity

EPS (TTM)

-2.16

EPS next Y

EPS next Q

EPS this Y

20.67%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

69.77%

SMA20

-8.93%

SMA50

7.59%

SMA100

-13.37%

Inst Own

17.86%

Inst Trans

0.28%

ROA

-46%

ROE

-43%

ROC

-0.61%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

42.76M

Shs Float

13.51M

Target Price

52W Range

6.54-21.5

52W High

-55.57%

52W Low

+55.5%

RSI

59.24

Rel Volume

1.16

Avg Volume

262.74K

Volume

304.04K

Perf Week

20.39%

Perf Month

-8.98%

Perf Quarter

-23.02%

Perf Half Y

-30.99%

Beta

2.46164

Volatility

0.38%, 0.61%

Prev Close

10.02%

Price

9.33

Change

12.68%

CMPS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-0.77	-1.14	-3.55	-1.79	-2.16
Operating cash flow per share	-0.57	-1.03	-2.44	-1.69	-2.48
Free cash flow per share	-0.58	-1.04	-2.44	-1.7	-2.5
Cash per share	1.33	1.45	11.2	6.83	3.37
Book value per share	-0.83	-1.76	11.57	7.11	4.27
Tangible book value per share	-0.83	-1.76	11.57	7.11	4.27
Share holders equity per share	-0.83	-1.76	11.57	7.11	4.27
Interest debt per share	0	1.22	0	0.09	0.05
Market cap	500.51M	500.51M	809.48M	883.95M	340.76M
Enterprise value	477.6M	496.63M	619.16M	614.32M	199.49M
P/E ratio	-37.86	-25.52	-13.42	-12.32	-3.72
Price to sales ratio	0	0	0	0	0
POCF ratio	-51.07	-28.1	-19.56	-13.05	-3.23
PFCF ratio	-50.4	-27.84	-19.5	-12.98	-3.21
P/B Ratio	-34.83	-16.47	4.12	3.11	1.88
PTB ratio	-34.83	-16.47	4.12	3.11	1.88
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-36.19	-25.42	-10.29	-8.61	-2.2
EV to operating cash flow	-48.73	-27.88	-14.96	-9.07	-1.89
EV to free cash flow	-48.09	-27.62	-14.92	-9.02	-1.88
Earnings yield	-0.03	-0.04	-0.07	-0.08	-0.27
Free cash flow yield	-0.02	-0.04	-0.05	-0.08	-0.31
Debt to equity	-2.84	-2.07	0.04	0.06	0.09
Debt to assets	1.54	1.94	0.03	0.05	0.08
Net debt to EBITDA	1.74	0.2	3.16	3.78	1.56
Current ratio	14.24	1.35	29.36	19.55	12.29
Interest coverage	0	0	0	0	0
Income quality	0.74	0.91	0.69	0.94	1.15
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0	0.01
Capex to revenue	0	0	0	0	0
Capex to depreciation	-5.91	-2.62	-1.17	-1.91	-1.81
Stock based compensation to revenue	0	0	0	0	0
Graham number	3.79	6.71	30.4	16.94	14.4
ROIC	0.62	1.12	0.29	0.34	1.18
Return on tangible assets	-0.5	-0.61	-0.3	-0.24	-0.46
Graham Net	-0.94	-1.96	11.05	6.63	3.27
Working capital	24.43M	8.3M	195.51M	280.19M	176.06M
Tangible asset value	-14.37M	-30.39M	196.56M	284.41M	181.28M
Net current asset value	-14.48M	-30.61M	195.51M	278.81M	175.64M
Invested capital	0	-0.69	0	0.01	0.01
Average receivables	0	3.68M	5.5M	8.5M	13.42M
Average payables	0	1.01M	2.04M	2.66M	3.66M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.92	0.65	-0.31	-0.25	-0.5
Capex per share	-0.01	-0.01	-0.01	-0.01	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-0.61	-0.5	-0.5	-0.43	-0.73
Operating cash flow per share	-0.53	-0.55	-0.42	-0.45	-1.07
Free cash flow per share	-0.54	-0.55	-0.43	-0.45	-1.07
Cash per share	6.53	5.8	4.88	4.07	3.37
Book value per share	6.8	6.17	5.29	4.58	4.27
Tangible book value per share	6.8	6.17	5.29	4.58	4.27
Share holders equity per share	6.8	6.17	5.29	4.58	4.27
Interest debt per share	0.09	0.07	0.07	0.05	0.05
Market cap	924.52M	541.85M	459.58M	456.3M	340.76M
Enterprise value	654.9M	301.16M	255.39M	285.48M	199.49M
P/E ratio	-9.01	-6.4	-5.46	-6.21	-2.75
Price to sales ratio	0	0	0	0	0
POCF ratio	-41.33	-23.43	-25.53	-23.99	-7.52
PFCF ratio	-41.16	-23.35	-24.95	-24	-7.5
P/B Ratio	3.25	2.09	2.05	2.35	1.88
PTB ratio	3.25	2.09	2.05	2.35	1.88
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-25.68	-14.36	-12.23	-15.72	-6.49
EV to operating cash flow	-29.28	-13.02	-14.18	-15.01	-4.4
EV to free cash flow	-29.16	-12.98	-13.87	-15.01	-4.39
Earnings yield	-0.03	-0.04	-0.05	-0.04	-0.09
Free cash flow yield	-0.02	-0.04	-0.04	-0.04	-0.13
Debt to equity	0.06	0.05	0.06	0.15	0.09
Debt to assets	0.05	0.05	0.06	0.13	0.08
Net debt to EBITDA	10.57	11.47	9.78	9.4	4.6
Current ratio	19.55	22.82	17.53	7.4	12.29
Interest coverage	0	0	0	0	0
Income quality	0.87	1.09	0.86	1.04	1.46
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0.02	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1.79	-1.52	-4.43	0	-1.11
Stock based compensation to revenue	0	0	0	0	0
Graham number	9.68	8.36	7.68	6.67	8.37
ROIC	0.11	0.12	0.15	0.18	0.34
Return on tangible assets	-0.09	-0.08	-0.09	-0.08	-0.16
Graham Net	6.34	5.74	4.85	3.69	3.27
Working capital	280.19M	254.87M	218.76M	188.92M	176.06M
Tangible asset value	284.41M	259.57M	224.59M	194.56M	181.28M
Net current asset value	278.81M	254.03M	217.94M	188.49M	175.64M
Invested capital	0.01	0.01	0.01	0.01	0.01
Average receivables	9.64M	12.41M	15.28M	17.54M	16.87M
Average payables	2.65M	2.31M	2.7M	11.62M	12.32M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.09	-0.08	-0.09	-0.09	-0.17
Capex per share	0	0	-0.01	0	0

CMPS Frequently Asked Questions

What is COMPASS Pathways plc stock symbol ?

COMPASS Pathways plc is a GB stock and trading under the symbol CMPS

What is COMPASS Pathways plc stock quote today ?

COMPASS Pathways plc stock price is $9.33 today.

Is COMPASS Pathways plc stock public?

Yes, COMPASS Pathways plc is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 262.74K
Market Capitalization 356.22M
Employee 116
CEO Mr. Kabir Nath M.A., M.B.A.
Headquarters London,GB
IPO Date 2020-09-18
Website https://compasspathways.com

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.